Paper Details

  1. Home
  2. Paper Details

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Author: BisagaAdam, CarpenterKenneth M, GlassAndrew, HaneyMargaret, LevinFrances R, MarianiJohn J, MishlenKaitlyn, NunesEdward V, PavlicovaMartina, RabyWilfrid N, SullivanMaria A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Dronabinol, a cannabinoid receptor type 1 partial agonist, reduced the severity of opioid withdrawal during acute detoxification but had no effect on rates of XR-naltrexone treatment induction and retention. Participants who elected to smoke marijuana during the trial were more likely to complete treatment regardless of treatment group assignment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Evidence suggests that the cannabinoid system is involved in the maintenance of opioid dependence. We examined whether dronabinol, a cannabinoid receptor type 1 partial agonist, reduces opioid withdrawal and increases retention in treatment with extended release naltrexone (XR-naltrexone...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26187456

データ提供：米国国立医学図書館（NLM）

Dronabinol: Navigating the Opioid Withdrawal Desert

The research delves into the complex and often difficult journey of opioid withdrawal and treatment, a journey often characterized by intense discomfort and a high risk of relapse. The study, conducted in the field of addiction medicine, examines the potential of dronabinol, a cannabinoid receptor type 1 partial agonist, to mitigate the harsh landscape of opioid withdrawal and improve retention in treatment with extended-release naltrexone (XR-naltrexone).

Finding Relief from Opioid Withdrawal: Dronabinol's Role

The study found that dronabinol significantly reduced the severity of opioid withdrawal during the inpatient detoxification phase, offering a potential oasis of relief for patients navigating this challenging period. While the impact on retention in treatment with XR-naltrexone wasn't as pronounced, the research suggests that dronabinol might play a crucial role in easing the initial stages of opioid withdrawal. However, it's important to note that the effect of dronabinol might vary depending on individual factors, including the patient's history of marijuana use.

The Importance of Personalized Treatment: Navigating the Individual's Journey

This research highlights the importance of personalized treatment in the complex landscape of addiction recovery. It emphasizes that individuals with a history of regular marijuana use may benefit from the therapeutic approach of dronabinol during opioid withdrawal. The study reminds us that each individual's journey is unique, and finding the most effective path requires a careful understanding of the individual's needs and preferences.

Dr.Camel's Conclusion

This research illuminates the potential of dronabinol as a supportive tool in navigating the arduous terrain of opioid withdrawal. It emphasizes the importance of individual factors in determining the effectiveness of treatment, urging us to tailor our approach to meet the unique needs of each patient. By understanding these individual factors, we can better guide patients towards a more successful journey towards recovery.

Date :
  1. Date Completed 2016-03-11
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26187456

DOI: Digital Object Identifier

NIHMS706399

Related Literature

Article Analysis
・Effects of dronabinol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.